Jun 2026 (Q2 FY26) — Jul 30, 2026
Veracyte Q2 FY26 — Strong Growth and Key Product Launches
Read the full callVeracyte (VCYT) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Veracyte earnings: last reported Thu, 30 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 150 | +15.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 15.3 | +19.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 25.5 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Guidance
What management said, and what became of it
15 of 15 judged targets kept · 14 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| OPTIMA trial completion / readout | expected to be completed in mid-2026 | Jun 2025 | The study met its primary endpoint and demonstrated that more than 2/3 of clinically high-risk patients may safely avoid chemotherapy without compromising outcomes. | Achieved |
| FY26 Afirma revenue growth | mid- to high single digits | Dec 2025 | For Afirma, we have increased our revenue guidance to approximately 12% to 14% year-over-year growth, driven by favorable year-to-date PPCs, ongoing ASP improvement and an anticipated no result rate benefit of approximately 3% for the year. | Revised Up |
| FY26 adjusted EBITDA margin | approximately 25% | Dec 2025 | We are maintaining our full year adjusted EBITDA guidance of greater than 26% | On Track |
14 of VERACYTE, INC.'s 29 targets are still open. See which are on track and which have gone quiet. The 3 above are the free sample; 26 more targets are in the full ledger.
Claimed
- Total revenue reached $150.3 million, representing 15% year-over-year growth.
- Adjusted EBITDA was $44 million, or 29.2% of revenue, up 23% year-over-year.
- Decipher Prostate revenue grew 20% year-over-year, driven by 17% volume growth.
- Afirma revenue grew 18% year-over-year, with 10% volume growth and sustained ASP gains.
- Successfully launched Prosigna LDT and TrueMRD for muscle invasive bladder cancer, expanding the portfolio into new growth areas.
Qualified
- Full-year Decipher Prostate volume guidance lowered by approximately 1,000 tests, primarily in the low-risk setting, due to NCCN guideline changes.
- Revenue guidance for Prosigna LDT and TrueMRD excludes contribution due to early launch stages and pending Medicare reimbursement for Prosigna.
Price
$43.8 +1.58% · +$0.68
Performance +22.2% 1Y
1Y: $35.83 on 17 Oct 2025 → $43.8. High $60.49 (26 Jun 2026), low $30.01 (27 Mar 2026).
- Previous close
- $43.12
- 52-week range
- $30.01 – $60.49
- One year
- +19.51%
Overview
- Symbol
- VCYT
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
15 of 15 judged targets kept · 14 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| OPTIMA trial completion / readout | expected to be completed in mid-2026 | Jun 2025 | The study met its primary endpoint and demonstrated that more than 2/3 of clinically high-risk patients may safely avoid chemotherapy without compromising outcomes. | Achieved |
| FY26 Afirma revenue growth | mid- to high single digits | Dec 2025 | For Afirma, we have increased our revenue guidance to approximately 12% to 14% year-over-year growth, driven by favorable year-to-date PPCs, ongoing ASP improvement and an anticipated no result rate benefit of approximately 3% for the year. | Revised Up |
| FY26 adjusted EBITDA margin | approximately 25% | Dec 2025 | We are maintaining our full year adjusted EBITDA guidance of greater than 26% | On Track |
Claimed
- Total revenue reached $150.3 million, representing 15% year-over-year growth.
- Adjusted EBITDA was $44 million, or 29.2% of revenue, up 23% year-over-year.
- Decipher Prostate revenue grew 20% year-over-year, driven by 17% volume growth.
- Afirma revenue grew 18% year-over-year, with 10% volume growth and sustained ASP gains.
- Successfully launched Prosigna LDT and TrueMRD for muscle invasive bladder cancer, expanding the portfolio into new growth areas.
Qualified
- Full-year Decipher Prostate volume guidance lowered by approximately 1,000 tests, primarily in the low-risk setting, due to NCCN guideline changes.
- Revenue guidance for Prosigna LDT and TrueMRD excludes contribution due to early launch stages and pending Medicare reimbursement for Prosigna.
The full ledger
Open VERACYTE, INC.’s full ledger
A free account opens 5 company ledgers a month. All 29 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — May 5, 2026
Veracyte Q1 FY26 — Strong Revenue and Volume Growth, Exceeding Profitability Expectations
Read the full callDec 2025 (Q4 FY25) — Feb 25, 2026
Veracyte Q4 FY25 — Strong Core Growth and Early Profitability Target Achievement
Read the full callEvery analysed call
Veracyte earnings calls (VCYT)
Financials
What the filings say
Net profit, year on year: +2701% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 116 | 119 | 114 | 130 | 132 | 141 | 139 | 150 |
| Expenses | 67 | 75 | 77 | 95 | 68 | 65 | 79 | 86 |
| Operating profit | 12 | 4 | 3 | -5 | 23 | 37 | 23 | 23 |
| Operating margin | 10.4% | 3.5% | 2.5% | −4.0% | 17.4% | 26.4% | 16.3% | 15.3% |
| Profit before tax | 17 | 3 | 7 | 1 | 19 | 41 | 30 | 27 |
| Tax rate | 10.1% | −48.5% | 5.1% | 178.4% | −1.3% | −1.3% | 4.2% | 3.9% |
| Net profit | 15 | 5 | 7 | -1 | 19 | 41 | 29 | 25 |
| EPS ($ per share) | 0.20 | — | 0.09 | -0.01 | 0.24 | — | 0.36 | 0.32 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -234 | -247 | -282 | -357 | -394 | -468 | -444 | -378 |
| Total liabilities | 41 | 36 | 36 | 91 | 81 | 71 | 124 | 96 |
| Fixed assets | 9 | 9 | 9 | 15 | 18 | 21 | 23 | 22 |
| Investments | — | — | — | — | — | — | — | 50 |
| Total assets | 121 | 275 | 457 | 1,188 | 1,156 | 1,115 | 1,300 | 1,406 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -14 | -3 | -10 | -32 | 8 | 44 | 75 | 136 |
| Cash from investing | -2 | -43 | -4 | -739 | -29 | 15 | -56 | -9 |
| Cash from financing | 59 | 127 | 204 | 596 | 3 | 3 | 5 | -4 |
| Net cash flow | 44 | 81 | 190 | -176 | -19 | 62 | 23 | 124 |
| Capital expenditure | -2 | -3 | -3 | -5 | -9 | -10 | -11 | -10 |
| Free cash flow | -15 | -6 | -13 | -37 | -1 | 34 | 64 | 127 |
VCYT revenue by segment
| Segment | Q2 FY2024 | Q3 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Reportable | — | — | 100% | 100% | 100% | 100% | 100% | 100% | +15.5% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
VCYT operating KPIs by quarter
| KPI | Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|
| Tests delivered Afirma | — | ~17.2KWe delivered approximately 17,200 tests in the first quarter, representing 12% year-over-year volume growth.Source: earnings call transcript | ~18.6KWe delivered another strong quarter with approximately 18,600 tests, representing 10% year-over-year volume growth and 18% revenue growth.Source: earnings call transcript | — |
| Tests delivered | ~48KWe grew total volume to approximately 48,000 tests, a 16% increase over the same period in 2024 and generated $52.6 million of cash from operations to end the quarter with $412.9 million of cash and cash equivalents on hand.Source: earnings call transcript | ~47.6KTotal volume increased to approximately 47,600 tests, up 17% compared to the same period in 2025, and we generated $35.2 million of cash from operations, ending the quarter with $439.1 million in cash, cash equivalents and short-term investments.Source: earnings call transcript | — | — |
| Testing volume | ~45.5KTotal testing volume was approximately 45,500 tests, an increase of 16% over the prior year period.Source: earnings call transcript | ~45.2KTotal testing volume was approximately 45,200 tests, representing 19% growth year-over-year. Testing ASP was $2,986, up 6% compared to the prior year and inclusive of approximately $4 million of prior period collections or PTCs.Source: earnings call transcript | 48.389KTotal testing volume was 48,389 tests, representing 14% year-over-year growth.Source: earnings call transcript | — |
| Testing ASP | ~$2,984Testing ASP was approximately $2,984, an increase of 4% compared to the prior year, driven primarily by the impact of higher prior period collections or PPCs.Source: earnings call transcript | $2,986Total testing volume was approximately 45,200 tests, representing 19% growth year-over-year. Testing ASP was $2,986, up 6% compared to the prior year and inclusive of approximately $4 million of prior period collections or PTCs.Source: earnings call transcript | $3,010Testing ASP was $3,010, up 4% to the prior year and inclusive of approximately $4.5 million of prior period collections or PTCs.Source: earnings call transcript | +0.8% |
| Normalized testing ASP | $2,875Normalized ASP was also higher at $2,875, a 1% increase compared to the prior year period after adjusting for the approximate impact of $5 million of PPCs in the quarter.Source: earnings call transcript | $2,900Excluding PTCs, normalized ASP increased 3% to $2,900, driven by continued strong collections.Source: earnings call transcript | ~$2,900Excluding PTCs, normalized ASP increased 3% to approximately $2,900, driven by the benefits of operational efforts put into place over the course of 2025, which have led to sustained pricing gains in the first half of this year.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Insider filings
115 filings between Oct 28, 2025 and Sep 21, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$20.67M
55 sales by 11 insiders
95% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 25
- Award — granted as compensation
- 7
- Option exercise — converted options into shares
- 28
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Stapley Marc | — | $8.56M | Jun 4, 2026 |
| JONES EVAN/ FA | — | $2.00M | Nov 25, 2025 |
| Chambers Rebecca | — | $1.91M | Sep 4, 2026 |
| McGuire Annie | — | $1.72M | Sep 4, 2026 |
| Wygant Jonathan | — | $1.54M | May 22, 2026 |
| EASTHAM KARIN | — | $1.49M | Jun 18, 2026 |
| Leite John | — | $1.25M | Sep 21, 2026 |
| Febbo Phillip G. | — | $1.05M | Sep 4, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 21, 2026 | Leite John Global Chief Commercial Off | Sale 10b5-1 plan | 4,015 | $160.6K |
| Sep 14, 2026 | Holstein Jens Director | Sale 10b5-1 plan | 5,000 | $204.7K |
| Sep 4, 2026 | Chambers Rebecca Chief Financial Officer | Sale 10b5-1 plan | 2,477 | $106.0K |
| Sep 4, 2026 | Febbo Phillip G. Chief Scientific & Med Officer | Sale 10b5-1 plan | 10,405 | $446.3K |
| Sep 4, 2026 | Chambers Rebecca Chief Financial Officer | Sale 10b5-1 plan | 1,175 | $51.4K |
| Sep 4, 2026 | Febbo Phillip G. Chief Scientific & Med Officer | Sale 10b5-1 plan | 2,705 | $118.1K |
| Sep 4, 2026 | McGuire Annie EVP, General Counsel | Sale 10b5-1 plan | 2,154 | $92.2K |
| Sep 4, 2026 | McGuire Annie EVP, General Counsel | Sale 10b5-1 plan | 1,100 | $48.0K |
| Sep 2, 2026 | Febbo Phillip G. Chief Scientific & Med Officer | Tax withheld 10b5-1 plan | 3,639 | $163.3K |
| Sep 2, 2026 | Stapley Marc Chief Executive Officer | Tax withheld | 8,782 | $394.1K |
| Sep 2, 2026 | Chambers Rebecca Chief Financial Officer | Tax withheld 10b5-1 plan | 3,603 | $161.7K |
| Sep 2, 2026 | Leite John Global Chief Commercial Off | Tax withheld | 3,961 | $177.8K |
| Sep 2, 2026 | Wygant Jonathan VP, Chief Accounting Officer | Tax withheld | 1,361 | $61.1K |
| Sep 2, 2026 | McGuire Annie EVP, General Counsel | Tax withheld 10b5-1 plan | 3,215 | $144.3K |
| Sep 1, 2026 | Bhanji Muna Director | Sale 10b5-1 plan | 1,864 | $80.1K |
| Jun 18, 2026 | EASTHAM KARIN Director | Sale 10b5-1 plan | 3,200 | $168.9K |
| Jun 18, 2026 | EASTHAM KARIN Director | Sale 10b5-1 plan | 529 | $28.3K |
| Jun 11, 2026 | Holstein Jens Director | Award | 5,272 | $0 |
| Jun 11, 2026 | Shafer David Brent Director | Award | 5,272 | $0 |
| Jun 11, 2026 | EASTHAM KARIN Director | Award | 5,272 | $0 |
| Jun 11, 2026 | JONES EVAN/ FA Director | Award | 5,272 | $0 |
| Jun 11, 2026 | Miller Thomas F. Director | Award | 5,272 | $0 |
| Jun 11, 2026 | Barr Eliav Director | Award | 5,272 | $0 |
| Jun 11, 2026 | Bhanji Muna Director | Award | 5,272 | $0 |
| Jun 11, 2026 | EPSTEIN ROBERT S Director | Award | 5,272 | $0 |
| Jun 4, 2026 | Stapley Marc Chief Executive Officer | Option exercise 10b5-1 plan | 138,051 | $5.05M |
| Jun 4, 2026 | Stapley Marc Chief Executive Officer | Sale 10b5-1 plan | 138,051 | $6.92M |
| Jun 4, 2026 | Leite John Global Chief Commercial Off | Sale 10b5-1 plan | 13,975 | $699.7K |
| Jun 4, 2026 | McGuire Annie EVP, General Counsel | Sale 10b5-1 plan | 1,400 | $69.0K |
| Jun 4, 2026 | McGuire Annie EVP, General Counsel | Sale 10b5-1 plan | 1,776 | $89.0K |
| Jun 4, 2026 | Chambers Rebecca Chief Financial Officer | Sale 10b5-1 plan | 1,961 | $98.2K |
| Jun 4, 2026 | Chambers Rebecca Chief Financial Officer | Sale 10b5-1 plan | 1,600 | $78.9K |
| Jun 2, 2026 | Febbo Phillip G. Chief Scientific & Med Officer | Tax withheld 10b5-1 plan | 3,730 | $178.3K |
| Jun 2, 2026 | Stapley Marc Chief Executive Officer | Tax withheld 10b5-1 plan | 9,012 | $430.8K |
| Jun 2, 2026 | Wygant Jonathan VP, Chief Accounting Officer | Tax withheld | 1,361 | $65.1K |
| Jun 2, 2026 | Leite John Global Chief Commercial Off | Tax withheld 10b5-1 plan | 4,059 | $194.0K |
| Jun 2, 2026 | Chambers Rebecca Chief Financial Officer | Tax withheld 10b5-1 plan | 3,693 | $176.5K |
| Jun 2, 2026 | McGuire Annie EVP, General Counsel | Tax withheld 10b5-1 plan | 3,292 | $157.4K |
| May 22, 2026 | Wygant Jonathan VP, Chief Accounting Officer | Sale | 24,000 | $1.09M |
| May 22, 2026 | Wygant Jonathan VP, Chief Accounting Officer | Option exercise | 24,000 | $595.2K |
| May 20, 2026 | EPSTEIN ROBERT S Director | Sale 10b5-1 plan | 10,000 | $440.1K |
| May 6, 2026 | McGuire Annie SVP, General Counsel | Sale 10b5-1 plan | 5,102 | $204.1K |
| May 6, 2026 | McGuire Annie SVP, General Counsel | Sale 10b5-1 plan | 5,102 | $194.1K |
| Apr 10, 2026 | Haas Kevin Richard Chief Dev and Tech Officer | Award | 44,221 | $0 |
| Mar 6, 2026 | Stapley Marc Chief Executive Officer | Award | 92,099 | $0 |
| Mar 6, 2026 | Wygant Jonathan VP, Chief Accounting Officer | Award | 10,525 | $0 |
| Mar 6, 2026 | Leite John Chief Commercial Officer-CLIA | Award | 6,578 | $0 |
| Mar 6, 2026 | Leite John Chief Commercial Officer-CLIA | Award | 36,181 | $0 |
| Mar 6, 2026 | McGuire Annie SVP, General Counsel | Award | 26,314 | $0 |
| Mar 6, 2026 | McGuire Annie SVP, General Counsel | Award | 32,892 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for VERACYTE, INC.
Free account. Everything above stays public.
Write why you follow VERACYTE, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading